Infectious diseases kill over 17 million people each year, according to the WHO, which is why vaccine-specialist Valneva is continuing to grow and develop the next generation of vaccines. Janet Hoogstraate, chair of the Management Board of Valneva Sweden, explains the high-quality of their manufacturing operations in the country and the company’s commitment to Sweden and its current development of vaccines against Lyme disease, and Chikungunya.
An important element of Valneva is its culture; we have involved the employees so they understand that they can influence the company as much as it influences them
